現行藥物外觀

中文名:耐血比注射劑 20

廠牌:KYOWA HAKKO KIRIN

Indication& Dosage: SC/I.V.

Adult:

Anemia in neoplastic disease, due to chemotherapy (non-myeloid malignancy):
SC, 2.25 μg/kg q1wk; or 500 μg q3wk.
Dose should be adjusted to maintain a target Hb up to 12 g/dL:

Anemia of chronic renal failure:
IV/SC, 0.45 μg/kg q1wk.
Dose should be adjusted every 2 to 4 wk by 20% or 25% to
maintain a target Hb up to 12 g/dL.
(Hb increases rate should’nt exceed 1g/dL in any 2-wk period).

Conversion from huEPO to darbepoetin alpha:

huEPO 2-3 times/wk→ darbepoetin alfa q1wk;
huEPO q1wk→ darbepoetin alfa q2wk .
The first dose of darbepoetin alfa should be administered at the time of next planned huEPO dose.

Pediatric≧1 yr
Anemia of chronic renal failure:
The use of darbepoetin alpha as the initial treatment to correct anemia in pediatric patients with chronic renal failure has not been studied.
Conversion from huEPO to darbepoetin alpha:

huEPO 2-3 times/wk→darbepoetin alfa once a wk;
huEPO q1wk→darbepoetin alfa q2wk .
The first dose of darbepoetin alfa should be administered at the time of next planned huEPO dose.
Dose should be adjusted to maintain a target Hb up to 12 g/dL:

藥劑部首頁	電子處方集	處方集PDA版	中西藥交互作用查詢	健保給付規定		不良反應通報系統	意見信箱

Darbepoetin Alfa		現行藥物外觀 中文名:耐血比注射劑 20 廠牌:KYOWA HAKKO KIRIN
Product name	NESP
Dosage form	(20mcg/0.5ml)針.
Indications
Administration & Dosage	Indication& Dosage: SC/I.V. Adult: Anemia in neoplastic disease, due to chemotherapy (non-myeloid malignancy): SC, 2.25 μg/kg q1wk; or 500 μg q3wk. Dose should be adjusted to maintain a target Hb up to 12 g/dL: Hemoglobin (Hb) Wkly doses Every-3-wk doses less than a 1 g/dL increase after 6 wk Increase dose to 4.5 μg/kg Increase dose to 4.5 μg/kg increases by more than 1 g/dL in a 2 wk period or exceeds 11 g/dL Reduce dose by 40% Reduce dose by 40% exceeds 13 g/dL Hold dose until Hb is less than 12 g/dL. Reinstitute at a 40% dose reduction. Hold dose until Hb is less than 12g/dL. Reinstitute at a 40% dose reduction. Anemia of chronic renal failure: IV/SC, 0.45 μg/kg q1wk. Dose should be adjusted every 2 to 4 wk by 20% or 25% to maintain a target Hb up to 12 g/dL. (Hb increases rate should’nt exceed 1g/dL in any 2-wk period). Conversion from huEPO to darbepoetin alpha: Previous wkly huEPO dose (IU) Wkly Aranesp dose (μg) less than 2,500 6.25 2,500 to 4,999 12.5 5,000 to 10,999 25 11,000 to 17,999 40 18,000 to 33,999 60 34,000 to 89,999 100 90,000 or greater 200 huEPO 2-3 times/wk→ darbepoetin alfa q1wk; huEPO q1wk→ darbepoetin alfa q2wk . The first dose of darbepoetin alfa should be administered at the time of next planned huEPO dose. Pediatric≧1 yr Anemia of chronic renal failure: The use of darbepoetin alpha as the initial treatment to correct anemia in pediatric patients with chronic renal failure has not been studied. Conversion from huEPO to darbepoetin alpha: Previous wkly huEPO dose (IU) Wkly Aranesp dose (μg) less than 1,500 insufficient data to determine dose 1,500 to 2,499 6.25 2,500 to 4,999 10 5,000 to 10,999 20 11,000 to 17,999 40 18,000 to 33,999 60 34,000 to 89,999 100 90,000 or greater 200 huEPO 2-3 times/wk→darbepoetin alfa once a wk; huEPO q1wk→darbepoetin alfa q2wk . The first dose of darbepoetin alfa should be administered at the time of next planned huEPO dose. Dose should be adjusted to maintain a target Hb up to 12 g/dL: Hemoglobin (Hb) Wkly doses no increase by at least a 1g/dL within 4 wk Increase dose by 25% increases by more than 1 g/dL in a 2- wk period Reduce dose by 25% approaches 12 g/dL Reduce dose by 25%
Contraindication	Hypersensitivity to darbepoetin or any component of the formulation; uncontrolled hypertension; pure red cell aplasia (due to darbepoetin or other erythropoietin protein drugs).
Precaution
Adverse reaction	Dizziness, headache, seizure ; arthralgia, myalgia; GI discomfort; hyper/hypotension, edema; thrombotic disorder; injection site thrombosis; respiratory disorders; fever.
Drug Interaction
Pregnancy Category	C
Notes

最近更新日期 2015年9月24日